



## Expert Opinions on the (Hemo)dialysate Sodium Prescription

Guest Editors:

### Prof. Dr. Manfred Hecking

Division of Nephrology and  
Dialysis, Department of Medicine  
III, Medical University of Vienna,  
Währinger Gürtel 18–20, 1090  
Vienna, Austria

### Prof. Dr. Peter Kotanko

1. Renal Research Institute, New  
York, NY, USA  
2. Division of Nephrology, Icahn  
School of Medicine at Mount  
Sinai, New York, NY, USA

### Dr. Jochen G. Raimann

Renal Research Institute, New  
York, NY, USA

Deadline for manuscript  
submissions:

**closed (31 March 2022)**

### Message from the Guest Editors

Numerous studies have attempted to help clinicians to prescribe the optimal sodium concentration in the dialysate bath of hemodialysis patients. However, studies on the associations between dialysate sodium concentrations and outcomes, such as intradialytic morbid events, cardiac morphology, cardiovascular disease, risk of hospitalizations and mortality, have been heavily debated. The scarcity of unconfounded insights from adequately powered randomized studies has complicated the conversation.

In anticipation of insights from adequately powered studies, this Special Issue aims to amalgamate the current opinions of experts in the field informing the community on how to approach this complex topic in their clinical practice.

**Specific Aim:** *“You are being put in charge as the Medical Director of a newly built dialysis clinic in your country. In consideration of available resources and reimbursement policies, how would you prescribe the dialysate sodium concentration for your patients? What would your approach be and why?”*

Please provide your opinion statement in no less than 500 words.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Francesco Locatelli**

Former Director, Department of  
Nephrology and Dialysis,  
Alessandro Manzoni Hospital,  
23900 Lecco, Italy

## Message from the Editor-in-Chief

In recent years, we have been witnessing dramatically increased interest in the treatment of chronic kidney disease, e.g., diabetic kidney disease, glomerular disease, or autosomal dominant polycystic kidney disease, but also aimed more generally on the progression of chronic kidney disease and the complications of chronic kidney disease, such as anemia, or hyperkalemia. This progress has led to changing paradigms as reflected by several recently published KDIGO guidelines which now need to be updated much more frequently than before. To personalize treatment, we also need better diagnostic methods, including validated biomarkers reflecting the activity of the disease (including response to treatment) and predicting outcomes.

*Kidney and Dialysis* aims to cover most of these areas not only in terms of feature reviews, but also original articles, and to keep the reader updated on recent progress in nephrology and dialysis.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **ESCI (Web of Science)**, **Scopus** and **other databases**.

**Journal Rank:** JCR - Q2 (Urology and Nephrology) / CiteScore - Q2 (Medicine (miscellaneous))

## Contact Us

---

*Kidney and Dialysis* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/kidneydial](http://mdpi.com/journal/kidneydial)  
[kidneydial@mdpi.com](mailto:kidneydial@mdpi.com)  
[X@Kidneydial\\_MDPI](https://twitter.com/Kidneydial_MDPI)